SEARCH:   Advanced

Blood, 1 February 2004, Vol. 103, No. 3, pp. 1158-1165. Prepublished online as a Blood First Edition Paper on October 2, 2003; DOI 10.1182/blood-2003-04-1098. This Article Full Text (PDF) All Versions of this Article: 2003-04-1098v1 103/3/1158    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Godfrey, W. R Articles by Blazar, B. R Search for Related Content PubMed PubMed Citation Articles by Godfrey, W. R Articles by Blazar, B. R Social Bookmarking                   What's this? Submitted April 9, 2003 Accepted September 27, 2003 Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation Wayne R Godfrey*, Mark R Krampf, Patricia A Taylor, and Bruce R Blazar Departments of Medicine and Pediatrics, University of Minnesota, Minneapolis, MN, USA * Corresponding author; email: godfr007{at}umn.edu. Eliminating alloreactive cells from T cell populations would enable the transfer of immune function to stem cell transplant patients. However, high efficiency depletion has proved difficult to achieve. We sought to develop ex vivo approaches for the maximal depletion of alloreactive CD4+ T cells. Using a flow cytometric cell sorting approach after MLR culture, we have found that sorted CFSEbright (non-divided) and activation antigen-negative cells are markedly depleted of alloreactivity. With HLA-mismatched PBMC stimulators we have consistently attained (90-95%) depletion of alloreactivity. Importantly, when purified matured monocyte derived dendritic cells (DCs) are used as stimulators, a 100-fold (99%) reduction in alloreactivity was attained, resulting in abrogation of the secondary MLR. Significantly, the CFSEbright CD25(-) cells recovered from these cultures retained general immunoreactivity, including responses to Candida and CMV antigens. In addition, a CFSE based approach was tested and found to be sufficient for GVHD prevention in vivo, in an MHC class II disparate murine model. This efficient approach to selectively deplete mature alloantigen-specific T cells, may permit enhanced immune reconstitution without GVHD. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: O. Bohana-Kashtan, S. Morisot, R. Hildreth, C. Brayton, H. I. Levitsky, and C. I. Civin Selective Reduction of Graft-versus-Host Disease-Mediating Human T Cells by Ex Vivo Treatment with Soluble Fas Ligand J. Immunol., July 1, 2009; 183(1): 696 - 705. [Abstract] [Full Text] [PDF] L. BIAN, Z.-K. GUO, H.-X. WANG, J.-S. WANG, H. WANG, Q.-F. LI, YUE-FENGYANG, F.-J. XIAO, C.-T. WU, and L.-S. WANG In Vitro and In Vivo Immunosuppressive Characteristics of Hepatocyte Growth Factor-modified Murine Mesenchymal Stem Cells In Vivo, January 1, 2009; 23(1): 21 - 27. [Abstract] [Full Text] [PDF] T. M. Friedman, K. Goldgirsh, S. A. Berger, J. Zilberberg, J. Filicko-O'Hara, N. Flomenberg, M. Donato, S. D. Rowley, and R. Korngold Overlap between in vitro donor antihost and in vivo posttransplantation TCR V{beta} use: a new paradigm for designer allogeneic blood and marrow transplantation Blood, October 15, 2008; 112(8): 3517 - 3525. [Abstract] [Full Text] [PDF] J. K. Davies, J. G. Gribben, L. L. Brennan, D. Yuk, L. M. Nadler, and E. C. Guinan Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies Blood, September 15, 2008; 112(6): 2232 - 2241. [Abstract] [Full Text] [PDF] S. Mielke, R. Nunes, K. Rezvani, V. S. Fellowes, A. Venne, S. R. Solomon, Y. Fan, E. Gostick, D. A. Price, C. Scotto, et al. A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique Blood, April 15, 2008; 111(8): 4392 - 4402. [Abstract] [Full Text] [PDF] S. Mielke, K. Rezvani, B. N. Savani, R. Nunes, A. S. M. Yong, J. Schindler, R. Kurlander, V. Ghetie, E. J. Read, S. R. Solomon, et al. Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantion in elderly patients and association with acute graft-versus-host disease Blood, September 1, 2007; 110(5): 1689 - 1697. [Abstract] [Full Text] [PDF] T. C. Wehler, M. Nonn, B. Brandt, C. M. Britten, M. Grone, M. Todorova, I. Link, S. A. Khan, R. G. Meyer, C. Huber, et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines Blood, January 1, 2007; 109(1): 365 - 373. [Abstract] [Full Text] [PDF] P. J. Amrolia, G. Muccioli-Casadei, H. Huls, S. Adams, A. Durett, A. Gee, E. Yvon, H. Weiss, M. Cobbold, H. B. Gaspar, et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation Blood, September 15, 2006; 108(6): 1797 - 1808. [Abstract] [Full Text] [PDF] B. J. Kappel, J. Pinilla-Ibarz, A. A. Kochman, J. M. Eng, V. M. Hubbard, I. Leiner, E. G. Pamer, G. Heller, M. R. M. van den Brink, and D. A. Scheinberg Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model Blood, March 1, 2006; 107(5): 2045 - 2051. [Abstract] [Full Text] [PDF] B. R Blazar and W. J Murphy Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD) Phil Trans R Soc B, September 29, 2005; 360(1461): 1747 - 1767. [Abstract] [Full Text] [PDF] S. R. Solomon, S. Mielke, B. N. Savani, A. Montero, L. Wisch, R. Childs, N. Hensel, J. Schindler, V. Ghetie, S. F. Leitman, et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation Blood, August 1, 2005; 106(3): 1123 - 1129. [Abstract] [Full Text] [PDF] H. J. P. M. Koenen, E. Fasse, and I. Joosten CD27/CFSE-Based Ex Vivo Selection of Highly Suppressive Alloantigen-Specific Human Regulatory T Cells J. Immunol., June 15, 2005; 174(12): 7573 - 7583. [Abstract] [Full Text] [PDF] W. R. Godfrey, D. J. Spoden, Y. G. Ge, S. R. Baker, B. Liu, B. L. Levine, C. H. June, B. R. Blazar, and S. B. Porter Cord blood CD4+CD25+-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function Blood, January 15, 2005; 105(2): 750 - 758. [Abstract] [Full Text] [PDF] D. Watson, G. Y. Zhang, M. Sartor, and S. I. Alexander "Pruning" of Alloreactive CD4+ T Cells Using 5- (and 6-)Carboxyfluorescein Diacetate Succinimidyl Ester Prolongs Skin Allograft Survival J. Immunol., December 1, 2004; 173(11): 6574 - 6582. [Abstract] [Full Text] [PDF] S. Reich-Zeliger, E. Bachar-Lustig, J. Gan, and Y. Reisner Tolerance Induction by Veto CTLs in the TCR Transgenic 2C Mouse Model. I. Relative Reactivity of Different Veto Cells J. Immunol., December 1, 2004; 173(11): 6654 - 6659. [Abstract] [Full Text] [PDF] S. L. R. Martins, L. S. St. John, R. E. Champlin, E. D. Wieder, J. McMannis, J. J. Molldrem, and K. V. Komanduri Functional assessment and specific depletion of alloreactive human T cells using flow cytometry Blood, December 1, 2004; 104(12): 3429 - 3436. [Abstract] [Full Text] [PDF] W. R. Godfrey, Y. G. Ge, D. J. Spoden, B. L. Levine, C. H. June, B. R. Blazar, and S. B. Porter In vitro-expanded human CD4+CD25+ T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures Blood, July 15, 2004; 104(2): 453 - 461. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020